Format

Send to

Choose Destination
Drug Discov Today. 2016 Jul;21(7):1147-54. doi: 10.1016/j.drudis.2016.05.004. Epub 2016 May 11.

Current therapies for premature ejaculation.

Author information

1
Department of Pharmacology, School of Pharmacy, Ankara University, Ankara, Turkey; Department of Urology, Tulane University Health Sciences Center, New Orleans, LA, USA. Electronic address: serapgur@ankara.edu.t.
2
Department of Pharmacology, Tulane University Health Sciences Center, New Orleans, LA, USA.
3
Department of Urology, Tulane University Health Sciences Center, New Orleans, LA, USA.

Abstract

Premature ejaculation (PE) subjectively affects 20-30% of men globally. Until recently, understanding of PE was hampered by the absence of a widely accepted definition, paucity of evidence-based clinical studies, and the absence of an appropriate animal model. Here, we elaborate on the current definition of PE, its pathogenesis, currently available therapies, and future treatment prospects. Most treatments for PE are 'off-label' and include selective serotonin reuptake inhibitors (SSRIs), topical anesthetics, tramadol, and phosphodiesterase type 5 (PDE5) inhibitors. Such knowledge of the benefit and limitations of each treatment will help to direct future drug design and formulations.

PMID:
27179987
DOI:
10.1016/j.drudis.2016.05.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center